SPOTLIGHT -
Drug Watch: Agents in late-stage development for the treatment of type 2 diabetes mellitus (August 2008)
Ozempic Reduces Kidney Disease Progression, Cardiovascular Events by 24%
The FLOW trial was stopped early based on an interim analysis that found the study met the criteria for efficacy.
Survey: Many Support Medicare Coverage of Weight Loss Drugs
Although most older adults support Medicare coverage of medications for weight loss drugs, only one in three favor paying more in premiums for this coverage, finds University of Michigan survey.
Express Scripts and Cigna Add Zepbound to Formularies
Zepbound, which was approved last month to treat obesity, is now available in U.S. pharmacies.
IQVIA: Drug Shortages are Growing
Shortages are growing because of disruption caused natural disasters and ingredient supply issues, as well as increased demand for certain drugs.
Pfizer Stops GLP-1 Obesity Trial Because of High Discontinuation Rates
Twice-daily danuglipron was being studied in a phase 2 study in adults with obesity. Pfizer is now conducting a pharmacokinetic study for a once-daily formulation.
Younger People Are Looking to GLP-1 Drugs for Weight Loss
A new survey finds that more people are using semaglutide and other GLP-1 therapies to lose less than 15 pounds.